• 1
    Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy. Ann Oncol. 1997; 7: 189195.
  • 2
    Laszlo J, Lucas VSJ. Emesis as a critical problem in chemotherapy. N Engl J Med. 1981; 305: 948949.
  • 3
    Gralla RJ. Controlling emesis in patients receiving cancer chemotherapy. Recent Results Cancer Res. 1991; 121: 6882.
  • 4
    Gralla RJ, Tyson LB, Kris MG, Clark RA. The management of chemotherapy-induced nausea and vomiting. Med Clin North Am. 1987; 71: 289301.
  • 5
    Kris MG, Cubeddu LX, Gralla RJ, et al. Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer. 1996; 78: 21932198.
  • 6
    Passalacqua R, Cocconi G, Bella M, et al. Double-blind, randomized trial for the control of delayed emesis in patients receiving cisplatin: comparison of placebo vs. adrenocorticotropic hormone (ACTH). Ann Oncol. 1992; 3: 481485.
  • 7
    Gandara DR, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ. Delayed emesis following high-dose cisplatin: a double-blind randomized comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer. 1993; 29A (Suppl 1): S35S38.
  • 8
    Kris MG, Gralla RJ, Tyson LB, Clark RA, Cirrincione C, Groshen S. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989; 7: 108114.
  • 9
    Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3: 13791384.
  • 10
    Navari RM, Madajewicz S, Anderson N, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol. 1995; 13: 24082416.
  • 11
    Roila F, Tonato M, Cognetti F, et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol. 1991; 9: 675678.
  • 12
    Smith DB, Newlands ES, Rustin GJ, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet. 1991; 338: 487490.
  • 13
    Hesketh PJ, Harvey WH, Harker WG, et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol. 1994; 12: 596600.
  • 14
    Roila F, Bracarda S, Tonato M, et al. Ondansetron in the prophylaxis of acute and delayed cisplatin-induced emesis. Clin Oncol. 1990; 2: 268272.
  • 15
    Hesketh P. Management of cisplatin-induced delayed emesis. Oncology. 1996; 53 (Suppl 1): 7885.
  • 16
    Gralla RJ, Rittenberg C, Peralta M, Lettow L, Cronin M. Cisplatin and emesis: aspects of treatment and a new trial for delayed emesis using oral dexamethasone plus ondansetron beginning at 16 hours after cisplatin. Oncology. 1996; 53 (Suppl 1): 8691.
  • 17
    Navari R, Reinhardt R, Gralla RJ, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1 receptor antagonist. N Engl J Med. 1999; 340: 190195.
  • 18
    Tattersall FD, Rycroft W, Cumberbatch M, et al. The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology. 2000; 39: 652663.
  • 19
    Cocquyt V, Van Belle S, Reinhardt R, et al. L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, compared to ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer. 2001; 37: 835842.
  • 20
    Campos D, Pereira JR, Reinhardt R, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol. 2001; 19: 17591767.
  • 21
    Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15: 103109.
  • 22
    Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol. 1998; 9: 811819.
  • 23
    National Cancer Institute. Cancer therapy evaluation program. Common toxicity criteria, version 2.0. Bethesda, MD: National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 1998.
  • 24
    Italian Group For Antiemetic Research. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet. 1992; 340: 9699.
  • 25
    Kris MG, Baltzer L, Pisters KMW, Tyson LB. Enhancing the effectiveness of the specific serotonin antagonists. Cancer. 1993; 72: 34363442.
  • 26
    Perez EA. Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis. Clin Therapeutics. 1996; 18: 578590.
  • 27
    Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med. 1981; 305: 905909.
  • 28
    Medical Economics Company. Physician's desk reference. 52nd ed. Montvale: Medical Economics Company, 1998: 28362838.